Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27644882 | 0.85 | CRHBP (0.49) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL30532627 | 0.83 | GAA (0.51) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL2290954 | 0.83 | CRHBP (0.53) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL11293633 | 0.82 | MAPT (0.49) | MAPTALDH1A1 | |
| SCHEMBL2222145 | 0.80 | GAA (0.55) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL28645163 | 0.80 | GAA (0.55) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL28426008 | 0.80 | KDM4A (0.47) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL10636873 | 0.79 | HTT (0.44) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL23027214 | 0.79 | GAA (0.62) | L3MBTL1HTTMEN1KMT2ALMNA | |
| SCHEMBL805646 | 0.79 | GAA (0.62) | L3MBTL1HTTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 618 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649317-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING ALZHEIMER'S DISEASE | Population Bio, Inc. (US) | 2025-11-19 | — | — | EP | claimed |
| US-12414986-B2 | Use of glutamine synthetase for treating fatty liver disease | THOERIS GMBH (AT) | 2025-09-16 | — | — | US | claimed |
| US-20250228921-A1 | TREATMENT OF ARGINASE 1 DEFICIENCY | IMMEDICA PHARMA AB (SE) | 2025-07-17 | — | — | US | claimed |
| US-12359184-B2 | Use of glutamine synthetase for treating hyperammonemia | THOERIS GMBH (AT) | 2025-07-15 | — | — | US | claimed |
| US-20250101119-A1 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING | REGENERON PHARMA (US) | 2025-03-27 | — | — | US | claimed |
| US-20250073318-A1 | MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 | AGIOS PHARMACEUTICALS, INC. | 2025-03-06 | — | — | US | claimed |
| US-20250000829-A1 | PHENYLBUTYRATE COMPOSITIONS FOR TREATING DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (“DEE”), AND STXBP1 DISORDERS | CORNELL UNIVERSITY (US) | 2025-01-02 | — | — | US | claimed |
| US-12139546-B2 | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | claimed |
| WO-2024194181-A1 | NH3 SCAVENGER FOR USE IN THE TREATMENT OF MOBILITY DISABILITY IN A POST-STROKE PATIENT | Merz Therapeutics GmbH (DE) | 2024-09-26 | — | — | WO | claimed |
| US-20240310389-A1 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING ALZHEIMER'S DISEASE | POPULATION BIO INC (US) | 2024-09-19 | — | — | US | claimed |
| US-20170087113-A1 | METHODS FOR TREATING UREA CYCLE DISORDERS TO PREVENT HYPERAMMONEMIC CRISES BY CONTROLLING BLOOD AMMONIA LEVELS | HORIZON THERAPEUTICS USA, INC. (FKA HORIZON PHARMA USA, INC.) | 2017-03-30 | — | — | US | claimed |
| US-9480673-B2 | Composition and method for treating neurodegenerative disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-11-01 | — | — | US | claimed |
| EP-3068383-A1 | SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2016-09-21 | — | — | EP | claimed |
| US-20160243071-A1 | SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2016-08-25 | — | — | US | claimed |
| WO-2016085887-A1 | TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES | UCL BUSINESS PLC (GB) | 2016-06-02 | — | — | WO | claimed |
| EP-3013372-A1 | METHODS FOR TREATING UREA CYCLE DISORDERS TO PREVENT HYPERAMMONEMIC CRISES BY CONTROLLING BLOOD AMMONIA LEVELS | Horizon Therapeutics, Inc. (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2015187641-A1 | METHODS FOR TREATING UREA CYCLE DISORDERS TO PREVENT HYPERAMMONEMIC CRISES BY CONTROLLING BLOOD AMMONIA LEVELS | HORIZON THERAPEUTICS, INC. (US) | 2015-12-10 | — | — | WO | claimed |
| WO-2015073816-A1 | SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2015-05-21 | — | — | WO | claimed |
| US-20150087703-A1 | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-03-26 | — | — | US | claimed |
| WO-2013149091-A1 | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243071-A1 | SOLID COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOF | PNLIP, LIPC, CETP | L3MBTL1 3285/4885HTT 808/4885MEN1 3215/4885 |
| US-20250073318-A1 | MITAPIVAT THERAPY AND MODULATORS OF CYTOCHROME P450 | PKM, PDK1, PKD2 | L3MBTL1 3253/4885HTT 1373/4885MEN1 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.